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Transforming growth factor-p canceled the hepa-
tocyte proliferation caused. by transforming growth 
factor-Of when the two substances were mixed and 
administered through a disconnected central portal 
vein branch after creation of an Eck fistula. In con-
trast. transforming growth factor-p had no antidotal 
action on the stimulatory effects of insulin or full test 
doses of insulinlike factor-2, hepatocyte growth factor, 
epidermal growth factor or triiodothymanine. A minor 
antidotal effect on hepatic stimulatory substance ac-
tivity could be detected., but only with hepatic stimu-
latory substance was given in doses smaller than those 
known to cause maximum stimulatory response. These 
results suggest a highly specific pharmacological and 
physiological interaction between transforming 
growth factor-a and transforming growth factor-p in 
the modulation of liver growth control. (HEPATOLOGY 
• q92; 16: 1267-1270.) 
The Eck fistula (portacaval shunt) in dogs is a useful 
tool in the identification and study of hepatic growth-
modulating substances, of which some of the most 
potent have little or no effect on hepatocytes in culture 
(1). This operation is followed by tripling of hepatocyte 
proliferation, atrophy of hepatocytes within 4 days to 
about half their original volume and establishment of a 
new stable state after 4 days (2). Growth stimulating 
substances, when infused into the tied-off central portal 
vein after this operation, augment further the 
heightened proliferation of the Eck fistula liver and 
prevent liver atrophy after creation ofthe fistula (1, 3-7). 
These effects have been termed hepatotrophic. In con-
trast, transforming growth factor-(3 (TGF-(3), a known 
inhibitor of hepatocyte proliferation in vitro (8, 9), has 
the opposite effect in that it suppresses hepatocyte 
proliferation after creation of the Eck fistula and further 
reduces the size of the atrophied hepatocytes (1). The 
striking TGF-(3 effect is easily overridden with in-
sulin (1). 
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In this study, we examined further the interaction of 
TGF -(3 with the five substances that were the most 
potently hepatotrophic in the Eck fistula model (1): 
insulin, insulinlike growth factor-2 (IGF -2), TGF -a, 
hepatocyte growth factor (HGF) and hepatic stimulatory 
substance (HSS). In addition, the interaction of TGF-(3 
was tested with other molecules: epidermal growth 
factor (EGF), which is highly stimulatory in vitro (10) 
but not in vivo; and triiodothymanine (T 3)' which causes 
feeble stimulation only in the in vivo system (1,11). The 
results revealed a strong, although not absolute, speci-
ficity of the TGF-a interactions with TGF-(3. 
MATERIALS AND METHODS 
The Experimental Model. Details of the experimental model 
have been described (1, 3, 4). In experiments testing a single 
drug, the left portal vein was used for infusion (Fig. lA) and the 
right portal vein was ligated. For double infusions, catheters 
were placed in both main portal branches and connected to 
separate infusion pumps (Fig. IB). The dogs were active after 
surgery and appeared clinically well. They were fed sugar 
water ad libitum on the day of surgery and a regular diet 
thereafter. 
The pathological endpoints were the same as those previ-
ously described (1-7). Four days after creation of the portacaval 
shunt, 0.2 mCiJkg of intravenous [3Hlthymidine was given 
(specific activity = 80 to 90 Cilmmol; Du Pont-New England 
Nuclear, Boston. MA). Two hours later, while dogs were under 
sodium phenobarbital anesthesia, specimens were taken from 
the left and right lobes of the liver and fixed in 10% normal 
buffered formalin. At autopsy, after each dog was killed with 
an overdose of anesthesia, the patency of the anastomosis and 
the correct position of the catheter tip were confirmed. The 
liver tissue was processed and stained with hematoxylin and 
eosin. 
Autoradiography was carried out with Kodak NTB2 liquid 
emulsion (Eastman Kodak Co., Rochester, NY) with an 
exposure time of at least 30 days. The number of replicating 
hepatocytes as an index of hepatocyte regeneration was 
determined by counting the number of [3Hlthymidine-Iabeled 
nuclei per 1,000 hepatocytes. The sizes of individual hepato-
cytes (index of hypertrophy or atrophy) were determined by 
tracing the outlines of at least 500 midzonal liver cells pro-
jected onto standard-thickness paper, cutting out the indi-
vidual silhouettes and weighing them. This method has been 
shown to be accurate in determining hepatocyte size and has 
been validated by planimetry and studies of unicellular or-
ganisms, the sizes of which have been determined directly (12). 
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FIG. 1. Eck fistula model for postoperative infusion into the (A) left 
portal vein and (B) the left and right portal vein. 
In control experiments (data not shown), we established 
that the vehicle used for the test substances is inert. Each 
animal served as its own control because the cell replication 
and cell sizes in the directly infused liver lobes could be 
compared with these parameters in the contralateral lobes that 
were not infused or infused with different solutions. In 
addition, we used as fresh controls animals not subjected to 
surgery and animals with Eck fistula only. Animals from the 
group of Eck fistula controls were killed on days 1 to 4 after 
surgery, enabling us to note the pace of change and the 
difference in changes of different liver lobes (Table 1). 
Growth Stimulatonl Tested. The hormones we used to 
stimulate growth were semisynthetic human insulin (E.R. 
Squibb & Sons, Inc., Princeton, NJ) and T 3 (Sigma Chemical 
Co., St. Louis, MO). Growth stimulating factors used were 
HSS produced in our laboratory (13); recombinant HGF (also 
called hematopoietin [14]), generously donated by Dr. George 
Michalopoulos of the University of Pittsburgh; IGF-2 and EGF 
<Collaborative Research, Inc., Bedford, MA); and TGF-a, 
(Peninsula Laboratories, Inc., Belmont, CAl. 
Growth Factor Inhibitonl Tested. TGF-13 <Collaborative 
Research, Inc., Bedford, MA) was infused alone (Fig. lA) or 
mixed with selected growth stimulating factors (Fig. 18) and 
infused into one of the branches of the portal vein. 
Statistical Analysis. Data are reported as mean ::!:: S.D. 
Student's one-tailed t test was used to determine the signifi-
cance of differences. A p value less than 0.05 was considered 
significant. 
RESULTS 
Controls. The day-to-day changes in the liver after 
creation of Eck fistula were the same as those reported 
previously (1-4) with rapid atrophy that was equal in the 
right and left lobes. We saw a nearly threefold increase 
in cell mitosis (Table 1). 
TGF·f3lnfusion. At a TGF-13 dose of 5 ng/kglday, th 
normal proliferative response of 1.5 to 4.5 labelet 
hepatocytes/1,000 hepatocytes was cut to about 2.: 
labeled hepatocytes/1,000 hepatocytes in the TGF -13-
infused left liver lobes; in the uninfused right lobes WE 
found a full proliferative effect. In addition, the hepa 
tocytes were significantly more atrophied in the lef1 
lobes than in the uninfused right lobes (Table 1). 
TGF· 13 Plus Growth Stimulator.. As previously reo 
ported (1), a strong hepatotrophic response was evident 
in the lobes infused only with insulin, IGF-2, HSS, HGF 
or TGF-a. Modest responses to T3 and EGF were seen 
(Table 2). TGF·13 at a dose 10 times greater than that 
shown to be antihepatotrophic in the control experi-
ments documented in Table 1 caused no reduction in 
these responses except for those induced by TGF-o. 
(Table 2). 
TGF-13 completely eliminated the TGF-a actvity. In 
addition, it suppressed the normally occurring prolifer-
ative response characteristic of Eck fistula and aggra-
vated hepatocyte atrophy (Table 2). 
Do8f!-respome Relatiomhip of HSS v •• that of TGF· 13. 
Although 50 ng/kglday HSS still had its full hepa-
totrophic effect after mixing with 50 ng/kglday TGF-p, 
smaller HSS doses of 25 and 10 ng were partly or 
completely inactivated after mixing with the fixed large 
dose of TGF-13 (Table 3). 
DISCUSSION 
TGF -13, a 25,000-Da homodimeric peptide, is known to 
be a powerful in vitro inhibitor of various cell types (15, 
16), including hepatocytes stimulated with EGF and 
TGF·a (9). During the liver regeneration that reaches its 
peak 24 hr after partial hepatectomy in rats, the tissue 
TGF.f3 level increases significantly, but not until after 
this peak of regeneration is reached. Thereafter the 
TGF -13 concentration rises four to eight times by 72 hr 
after hepatectomy and then recedes to the control level 
by 96 hr. Such findings have prompted speculation that 
TGF -13 modulates liver regeneration by counteracting 
the growth stimulation of TGF-a, EGF and other 
regeneration-promoting factors (17). 
In contrast to the classic "burst" ofliver regeneration 
after partial hepatectomy, the heightened cell renewal 
after creation of the Eck fistula builds to a new steady 
state within 4 days after surgery and remains constant 
thereafter. In this investigation it was demonstrated 
that 5 ng/kg/day TGF -13 prevented the increase in 
hepatocyte proliferation invariably seen in the Eck 
fistula liver. It also worsened the characteristic hepa-
tocyte atrophy. 
In subsequent experiments, 50 ng/kglday TGF-13 was 
infused to simulate the high concentrations of endog-
enous TGF-p seen during regeneration after hepa-
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No. of nays after 
Group dollS PCS 
1 2 No surgery 
2 3 1 
3 3 2 
4 3 3 
5 4 4 
6 3 4 
7 2 4 
PCS = portacaval shunt. 
ECK FISTULA AND TGF-13 
TABLE 1. Hepatocyte size and autoradiographic labeling 
~qdc-fi 
dOlle 
(ng/kgldayl 
5 
50 
No. of labeled hepatocytes per 1,000 hepatocytell" 
Left lobe 
1.55 ± O.lS 
1.43 ± 0.43 
6.33 ± MKU~ 
5.03 ± 0.27b 
4.4 ± 0.3b 
2.4 ± 0.5c• d 
2.1 ± 0.05e• d 
Right lobe 
1.55 ± 0.08 
1.36 ± 0.4 
6.26 ± 0.64b 
4.96 ± 0.3b 
4.2 ± 0.3b 
4.6 ± O.S 
4.9 ± 0.7 
1269 
Cell size unite" 
Left lobe 
0.161 ± 0.002 
0.192 ± 0.02 
0.134 ± 0.008b 
0.128 ± O.oogb 
0.095 ± O.Olb 
0.064 ± 0.02'" d 
0.071 ± 0.006e• d 
Right lobe 
0.160 ± 0.003 
0.192 ± 0.023 
0.134 ± O.oogb 
0.130 ± O.OOSb 
0.096 ± 0.015b 
0.103 ± 0.01 
0.106 ± 0.004 
Group 1: dogs that did not undergo surgery; groups 2 to 5: dogs 1 to 4 days after PCS; groups 6 and 7: dogs with PCS and 4-day continuous 
infusion of TGF·13 into the left branch of the portal vein. 
aData expressed as mean ± S.D. 
bp < 0.001 vs. groups 1 and 2. 
cp < 0.01 VB. own right lobe. 
d p < 0.05 vs. left lobe of group 5. 
TABLE 2. Hepatocyte size and autoradiographic labeling after continuous infusion of growth stimulating factor into the 
right portal vein branch and infusion of growth stimulating factor plus TGF-ji (50 nglkg/day) into the left portal infusion 
of branch 
No. of labeled hepatocytes 
per 1,000 hepatocytell" Cell size units'" 
No. of Stimulating DOlle Right lobe Right lobe 
Group subjects substances (ng/kgldayl Left lobe (no inhibitor) Left lobe (no inhibitor) 
1 3 Insulin 0.16 15.0 ± O.S 14.9 ± 0.4 0.lS7 ± 0.018 0.165 ± 0.01 
2 1 IGF-2 50 11.0 10.3 0.148 0.1477 
3 2 HSS 50 13.8 ± 0.2 13.3 ± 0.15 0.142 ± 0.006 0.143 ± 0.004 
4 1 HGF 50 11.3 11.2 0.164 0.163 
5 2 Ts 100 7.4 ± 0.65 7.3 ± O.S 0.126 ± 0.016 0.127 ± 0.013 
6 2 EGF 150 5.15 ± 0.2 5.05 ± 0.05 0.119 ± 0.001 0.120 ± 0.001 
7 2 TGF-a 50 3.4 ± 0.25b 12.6 ± 0.5 0.OS2 ± 0.006b 0.159 ± 0.002 
aData expressed as mean ± S.D. 
bp < 0.001. 
TABLE 3. Hepatocyte size and autoradiographic labeling after continuous infusion of HSS into the right portal vein branch 
and HSS plus TGF·ji (50 ng/kg/day) into the left portal vein branch 
No. of labeled hepatocytell per 1,000 hepatocytell" Cell size units 
No. of KSS 
Group subjectll (ng/kglday) Left lobe 
1 10 2.3 
2 1 25 5.8 
3 2 50 13.0 ± 0.2 
aData expressed as mean ± S.D. 
tecto my . These high concentrations are considered the 
result of the development of resistance to qdc-~ (18). In 
the 4 days after creation of the Eck fistula, the larger 
dose ofqdc-~ (50 ng/kglday) abrogated the stimulation 
usually caused by TGF-o.. Because the reactivity to 
TGF-a alone was fully retained in the contralateral 
lobes, it appeared that qdc-~ was inactivated almost 
completely with one pass through the liver. Under the 
same conditions of testing, all of the other potent 
hepatotrophic factors that were examined (insulin, 
Right lobe 
(no inhibitor) 
7.5 
9.2 
13.3 ± 0.15 
Left lobe 
0.093 
0.104 
0.142 ± 0.006 
Right lobe 
(no inhibitor) 
0.141 
0.153 
0.143 ± 0.004 
IGF-2, HGF, HSS, T 3 and EGF) were unaffected by 
mixing and coadministration with qdc-~K 
These data indicate that growth-stimulating factors of 
hepatocytes can be divided into two groups: those 
resistant to modulation by TGF -~ and those whose 
proliferation-inducing qualities are dramatically re-
duced or even canceled by qdc-~K However, it should 
also be emphasized that the foregoing classification of 
hepatic stimulatory factors according to their reaction to 
coadministration with qdc-~ depends in part on dose 
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selection. This was demonstrated when HSS (which is 
usually unaffected by qdc-~F was given in reduced 
quantities (lO or 25 ng/kg/day) that by themselves 
evoked minimum proliferative responses. Under these 
circumstances, the minor HSS-induced response could 
be eliminated with qdc-~K 
Further discussion of these findings does not seem 
warranted. However, we do emphasize the seemingly 
high degree of specificity of the qdc-~/qdc-a inter-
action. Even EGF, which ostensibly has the same 
binding sites as TGF -a (19), was not affected by TGF -13. 
This pharmacological specificity is consonant with a 
critical role of the balance of these growth factors in the 
control of cell proliferation, as has been proposed by 
others (20, 21). 
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